In the past, the ADCS has had an active and successful minority recruitment core. In this submission we have expanded the function of the recruitment core to improve recruitment to all protocols and to evaluate recruitment efforts at the site level as well as across all sites.
The specific aims of the recruitment core are as follows: 1. Identify a full range of recruitment and retention activities, including both successful previously tried and newly proposed. 2. Review protocols with Project Directors to reduce barriers to recruitment. Aspects of the protocol to be reviewed include subject eligibility, study procedures, and schedule of events. The goal of the review will be to avoid unnecessary restrictions, and to minimize subject burden while maintaining scientific rigor. 3. Support and train site staff in recruitment and retention efforts. While the sites have been chosen for their expertise in evaluation and treatment of cognitive deficits and dementia as well as their commitment to conduct clinical trials, many are less familiar with communication techniques that can maximize recruitment. This mandatory training will provide an opportunity to introduce the techniques and methods and provide a dialogue for specific needs. The trial sites will be evaluated continually throughout the trial and lags in recruitment will lead to additional contact from the trial PI and the recruitment core leader, and a site-specific remedial program will be developed, implemented and monitored for success. 4. Maximize minority participation. We will continue our efforts to insure that our sites provide maximum opportunity for participation by minority populations. We will include training at the sites. In addition, we will continue our efforts to bring on selected sites which primarily serve minority populations.

Public Health Relevance

Despite the long history by the NIH to ensure and enhance representation of ethnic minorities in biomedical research endeavors - significant disparities remain. The impact of the ongoing disparity is particularly negative when a disease is prevalent in minority populations. Moreover, clinical research results are must reflect the community at large. ADCS is committed to engaging in recruitment strategies as we strive to streamline and improve minority participation in all ADCS trials.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (02))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Amyloid and APOE ?4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82:1760-7
Mormino, Elizabeth C; Betensky, Rebecca A; Hedden, Trey et al. (2014) Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71:1379-85
Rafii, Michael S; Taylor, Curtis S; Kim, Hyun T et al. (2014) Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen 29:159-65
Whitehouse, Peter J (2014) The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. Biochem Pharmacol 88:677-81
Burstein, Aaron H; Grimes, Imogene; Galasko, Douglas R et al. (2014) Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 14:12
Donohue, Michael C; Jacqmin-Gadda, Hélène; Le Goff, Mélanie et al. (2014) Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10:S400-10
Samieri, Cécilia; Proust-Lima, Cécile; M Glymour, Maria et al. (2014) Subjective cognitive concerns, episodic memory, and the APOE ?4 allele. Alzheimers Dement 10:752-759.e1
Galasko, Douglas; Bell, Joanne; Mancuso, Jessica Y et al. (2014) Clinical trial of an inhibitor of RAGE-A? interactions in Alzheimer disease. Neurology 82:1536-42
Sperling, Reisa A; Rentz, Dorene M; Johnson, Keith A et al. (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6:228fs13
Papay, Kimberly; Xie, Sharon X; Stern, Matthew et al. (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83:826-33

Showing the most recent 10 out of 14 publications